Non-Calcium Phosphate Binders
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PMN.04 alerts
Get alerted when Policy MDN.CP.PMN.04 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization criteria, dosing limits, and continuation requirements for non-calcium phosphate binders (Auryxia, Fosrenol, Renvela, Renagel, Velphoro) for members (Medicaid line of business) with CKD/ESRD or specified indications.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Therapy - Hyperphosphatemia
Covered when ALL of the following are met
Initial Approval - Hyperphosphatemia
- 1) Diagnosis of hyperphosphatemia associated with CKD or ESRD.
- 2) Prescribed by or in consultation with a nephrologist, or member is on dialysis.
ALL of the following
- ONE of: a. Auryxia (ferric citrate), Fosrenol (lanthanum carbonate), or Renagel (sevelamer hydrochloride).
- b. Renvela: age ≥ 6 years.
- c. Velphoro: age ≥ 9 years.
ALL of the following
- ONE of: a. Failure of a 4-week trial of calcium acetate at up to maximally indicated doses (example failure: serum phosphorus > 5.5 mg/dL), unless contraindicated or clinically significant adverse effects are experienced.
- b. Hypercalcemia: corrected total serum calcium > 10.2 mg/dL within the previous 30 days.
- c. Plasma PTH < 150 pg/mL on two consecutive measurements in the past 180 days.
- d. History of severe vascular and/or soft-tissue calcifications.
- 5) For ferric citrate (Auryxia) or Renagel: Failure of a 4-week trial of Fosrenol (lanthanum carbonate), sevelamer hydrochloride or sevelamer carbonate at up to maximally indicated doses, unless clinically significant adverse effects are experienced or these agents are contraindicated.
ALL of the following
- ONE of: a. Age ≥ 18 years: Failure of a 4-week trial of Fosrenol (or generic) or Renvela (generic preferred) at up to maximally indicated doses, unless adverse effects or contraindications.
- b. Age ≥ 9 and < 18 years: Failure of a 4-week trial of Renvela (generic preferred) at up to maximally indicated doses, unless adverse effects or contraindications.
- 7) For Renvela: member must use generic sevelamer carbonate unless contraindicated or clinically significant adverse effects are experienced.
- 8) For Renagel: member must use generic sevelamer hydrochloride unless contraindicated or clinically significant adverse effects are experienced.
- 9) Dose does not exceed the per-drug maximums: Auryxia 12 tablets (2,520 mg ferric iron) per day; Fosrenol 4,500 mg/day; Renagel 13 g/day; Renvela 14 g/day; Velphoro 3,000 mg (6 tablets) per day.
Initial Therapy - Iron Deficiency Anemia (Auryxia)
Covered when ALL of the following are met
Initial Approval - Iron Deficiency Anemia (Auryxia)
- 1) Request is for Auryxia (ferric citrate).
- 2) Diagnosis of iron deficiency anemia with CKD not on dialysis.
- 3) Failure of a 4-week, adherent trial of alternative oral iron therapy (e.g., ferrous sulfate, ferrous fumarate, ferrous gluconate), unless contraindicated or clinically significant adverse effects are experienced.
- 4) Dose does not exceed 12 tablets (2,520 mg ferric iron) per day.
Continuation Therapy
Covered for continued therapy when ALL of the following are met
Continued Therapy - All Indications
- 1) Member is currently receiving medication via Centene benefit or previously met initial approval criteria; or continuity of care applies per state/product regulations.
- 2) Member is responding positively to therapy (examples: reduction in serum phosphorus from pretreatment level; maintenance of serum phosphorus < 5.5 mg/dL; increased hemoglobin).
- 3) If request is for a dose increase, the new dose does not exceed per-drug maximums: Auryxia 12 tablets (2,520 mg ferric iron)/day; Fosrenol 4,500 mg/day; Renagel 13 g/day; Renvela 14 g/day; Velphoro 3,000 mg (6 tablets)/day.
Non-FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation demonstrating efficacy and safety in accordance with the plan's off‑label use requirements (see off‑label use policy CP.PMN.53 for Medicaid or applicable evidence of coverage documents).
Requests for indications that fall outside FDA‑approved uses listed in this policy are not authorized unless the request includes adequate clinical evidence of efficacy and safety per the plan’s off‑label use review process (refer to off‑label use policy CP.PMN.53 or applicable evidence of coverage documents).
Uses that are non‑FDA approved and lack sufficient off‑label documentation as required by the referenced off‑label use policy are considered not medically necessary under this policy and therefore are not authorized.
Prior Authorization, Documentation, and Step Therapy Requirements
Prior authorization required for listed agents
Prior authorization is required for the listed non-calcium phosphate binders: ferric citrate (Auryxia), Fosrenol (brand), sevelamer carbonate (Renvela), sevelamer hydrochloride (Renagel), and sucroferric oxyhydroxide (Velphoro). The provider must document that the member meets all approval criteria when submitting the PA request.
- PA applies to Auryxia, Fosrenol (brand), Renvela, Renagel, and Velphoro.
- Provider must document that member meets all approval criteria.
PA implied with agent-specific dosing limits
Prior authorization is expected for non-calcium phosphate binders with dosing, indication, and maximum daily doses specified per agent in the policy; specific PA codes are not listed in this document.
- Appendix tables include dosing regimens and maximum doses for each agent (see Appendices B–C).
- The policy notes PA may be required for Renvela in some cases.
Required prior trials (step therapy)
Step therapy requirements: many agents require a prior trial of calcium acetate for 4 weeks at up to maximally indicated doses with failure defined (for example) as serum phosphorus > 5.5 mg/dL, unless contraindicated or clinically significant adverse effects occur.
- For Auryxia and Renagel, failure of a 4-week trial of Fosrenol or sevelamer products at maximally indicated doses is required unless contraindicated.
- For Velphoro age ≥18: failure of a 4-week trial of Fosrenol (or generic) or Renvela (generic preferred) at maximally indicated doses; age 9–17: failure of Renvela (generic preferred).
- For Auryxia used for iron deficiency anemia, failure of a 4-week adherent trial of alternative oral iron therapy is required.
Therapeutic alternatives and dosing (Appendix B)
Therapeutic alternatives and recommended dosing are listed in Appendix B (Therapeutic Alternatives); these preferred alternatives (e.g., calcium acetate, lanthanum, sevelamer dosing regimens) may be recommended in approval criteria and themselves may require prior authorization.
- Appendix B lists calcium acetate dosing (e.g., 2 capsules PO TID with meals; titrate to phosphorus < 6 mg/dL) and max total elemental calcium (1,500 mg/day).
- Appendix B lists lanthanum (Fosrenol) and sevelamer (Renvela) starting doses and maximum doses.
Submit supporting clinical documentation with PA request
Provider must submit documentation such as office chart notes, laboratory results, or other clinical information supporting that the member has met all approval criteria when requesting prior authorization.
- Include documentation of diagnosis, prescriber/nephrology consult or dialysis status, prior-trial results, relevant labs (serum phosphorus, calcium, PTH), and age/dose information as applicable.
Documentation expectations and rationale
Providers should document clinical rationale, supporting evidence, and member-specific information consistent with medical necessity guidance and applicable coverage documents when requesting coverage.
- Document why alternatives are not appropriate when exceptions to step therapy or generic use are requested.
- Provide relevant objective data (labs, trials, adverse effects) to support medical necessity.
Denial risk if required documentation or criteria not met
Requests missing documentation that the member meets all approval criteria — including diagnosis, prescriber/nephrology consult or dialysis status, required prior trials or contraindications, age/dose restrictions, and lab values — may be denied.
- Failure to provide documentation of prior trials (e.g., calcium acetate, Fosrenol/sevelamer) or relevant labs (serum phosphorus, corrected calcium, PTH) risks denial.
- Requests must show member meets agent-specific eligibility (age, dialysis status, generic use unless contraindicated).
Off‑label indications are not authorized without sufficient evidence
Requests for non–FDA approved (off-label) indications are not authorized by this policy unless sufficient documentation of efficacy and safety is provided according to the off-label use policies (CP.PMN.53 for Medicaid) or evidence of coverage documents.
- Off-label use must be supported by documentation meeting the referenced off-label policy to be considered.
- Lack of adequate off-label evidence will result in non-authorization per this policy.
Key Terms and Abbreviations
Clinical Background
Non‑calcium phosphate binders are indicated primarily to control serum phosphorus in patients with chronic kidney disease (CKD) on dialysis or with end‑stage renal disease (ESRD). Some agents have additional, agent‑specific indications; approval for any use not covered by this policy requires supporting documentation per the plan’s off‑label use requirements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.